IDEXX LABORATORIES INC /DE Accrued Marketing Costs, Current
IDEXX LABORATORIES INC /DE (IDXX) had Accrued Marketing Costs, Current of $89.96 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Payables and Accruals › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedMarketingCostsCurrent · last filed 2026-08-04
- 2026-06-30: Accrued Marketing Costs, Current $89.96M.
- 2026-03-31: Accrued Marketing Costs, Current $89.60M.
- 2025-12-31: Accrued Marketing Costs, Current $87.63M.
- 2025-09-30: Accrued Marketing Costs, Current $86.39M.
| Period end | Accrued Marketing Costs, Current | Accrued Marketing Costs, Current as first filed |
|---|---|---|
| 2026-06-30 | $89.96M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $89.60M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $87.63M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $86.39M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $84.97M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $74.86M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $78.19M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $75.63M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $83.76M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $80.84M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $84.39M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $84.42M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $82.04M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $77.11M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $72.25M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $74.05M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $76.70M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $74.29M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $79.47M 10-K · filed 2023-02-16 | |
| 2021-09-30 | $81.03M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $85.30M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $80.75M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $75.06M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $71.89M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $63.15M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $60.02M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $63.08M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $63.61M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $61.46M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $59.93M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $59.37M 10-K · filed 2020-02-14 | |
| 2017-12-31 | $56.66M 10-K · filed 2019-02-15 | |
| 2017-09-30 | $55.19M 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $54.10M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $48.70M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $49.06M 10-K · filed 2018-02-16 | |
| 2016-09-30 | $46.21M 10-Q · filed 2016-11-01 | |
| 2016-06-30 | $44.97M 10-Q · filed 2016-08-02 | |
| 2016-03-31 | $44.12M 10-Q · filed 2016-04-29 | |
| 2015-12-31 | $43.88M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $45.85M 10-Q · filed 2015-10-28 | |
| 2015-06-30 | $44.80M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $40.34M 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $36.02M 10-K · filed 2016-02-17 | |
| 2014-09-30 | $32.11M 10-Q · filed 2014-10-24 | |
| 2014-06-30 | $31.34M 10-Q · filed 2014-07-25 | |
| 2014-03-31 | $26.46M 10-Q · filed 2014-04-25 | |
| 2013-12-31 | $25.66M 10-K · filed 2015-02-17 | |
| 2013-09-30 | $26.66M 10-Q · filed 2013-10-22 | |
| 2013-06-30 | $26.72M 10-Q · filed 2013-07-23 | |
| 2013-03-31 | $25.07M 10-Q · filed 2013-04-23 | |
| 2012-12-31 | $26.37M 10-K · filed 2014-02-18 | |
| 2012-09-30 | $29.04M 10-Q · filed 2012-10-19 | |
| 2012-06-30 | $31.50M 10-Q · filed 2012-07-20 | |
| 2012-03-31 | $30.63M 10-Q · filed 2012-04-20 | |
| 2011-12-31 | $31.88M 10-K · filed 2013-02-19 | |
| 2011-09-30 | $30.00M 10-Q · filed 2011-10-21 | |
| 2011-06-30 | $29.94M 10-Q · filed 2011-07-22 | |
| 2010-12-31 | $23.32M 10-K · filed 2012-02-17 | $22.21M 10-Q · filed 2011-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |